英文药名: Toviaz(Fesoterodine Fumarate Tablets)
生产厂家: Pfizer Inc.
Generic Name for TOVIAZ
Fesoterodine fumarate 4mg, 8mg; ext-rel tabs.
Pharmacological Class for TOVIAZ
Muscarinic receptor antagonist.
Manufacturer of TOVIAZ
Indications for TOVIAZ
Overactive bladder (OAB) with urge urinary incontinence, urgency, and frequency.
Adult dose for TOVIAZ
Swallow whole. 4mg once daily; max 8mg once daily. Severe renal insufficiency (CrCl<30mL/min) or concomitant potent CYP3A4 inhibitors: max 4mg/day.
Children's dosing for TOVIAZ
Contraindications for TOVIAZ
Urinary or gastric retention. Uncontrolled narrow angle glaucoma.
Warnings/Precautions for TOVIAZ
Severe hepatic impairment: not recommended. Bladder outlet obstruction. Controlled narrow angle glaucoma. Hepatic or renal dysfunction. Myasthenia gravis. Decreased gastric motility. Exposure to high environmental temperatures. Pregnancy (Cat.C). Nursing mothers.
Interactions for TOVIAZ
Increased levels with CYP3A4 inhibitors (eg, erythromycin). CNS depression with alcohol, other CNS depressants.
Adverse Reactions for TOVIAZ
Dry mouth, constipation, urinary retention/UTI, blurred vision, dry eyes, back pain, insomnia, dyspepsia.
How is TOVIAZ supplied?
Pfizer Inc’s Toviaz (fesoterodine fumarate)
Pharmacology and Pharmacokinetics
The primary efficacy end point was the change in the number of micturitions per 24 hours. Coprimary end points were the change in the number of urge urinary incontinence episodes per 24 hours and the treatment response. Secondary efficacy end points were the change in mean voided volume per micturition and the number of continent days and urgency episodes per 24 hours. Tolerability and safety were assessed by evaluating adverse events, electrocardiograms, postvoid residual urine volume, laboratory parameters, and treatment withdrawals.
Treatment with 4- or 8-mg fesoterodine resulted in statistically significant improvements from baseline to end of treatment for the primary and coprimary end points compared with placebo (P <.05).
Results for most secondary end points, including mean voided volume per micturition, number of continent days, and number of urgency episodes per 24 hours, were also significantly improved versus placebo. The adverse events reported more frequently with fesoterodine than with placebo were dry mouth, constipation, and urinary tract infection.3
No dose adjustments are necessary with mild-to-moderate hepatic dysfunction. Patients with severe hepatic dysfunction should not take Toviaz, whereas it has not been studied in this patient population.
The most common side effects observed with Toviaz include dry mouth and constipation. The incidence of dry mouth was higher in patients receiving Toviaz 8 mg/day (35%) and those receiving 4 mg/day (19%), compared with those receiving placebo (7%). The incidence of constipation was lower in those patients receiving placebo (2%), compared with 4% of those taking Toviaz 4 mg/day and 6% of those taking 8 mg/day.2
富马酸非索罗定缓释片|Toviaz(Fesoterodine Fumarate Tablets)
简介： 英文药名: Toviaz(Fesoterodine Fumarate Tablets) 中文药名: 富马酸非索罗定缓释片 生产厂家: Pfizer Inc. 药品介绍 辉瑞（Pfizer）公司宣布美国FDA批准Toviaz（fesoterodine fumarate）缓释片治疗 ...